FGEN — FibroGen, Inc.

FibroGen Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $1.1 million for Q3 2025, up from $0.1 million in Q3 2024.
• Operating Costs: $6.5 million in Q3 2025, a significant decrease from $47.8 million in Q3 2024 (down 86%).
• R&D Expenses: $1.2 million in Q3 2025, down 94% from $20 million in Q3 2024.
• SG&A Expenses: $5.3 million, down 43% from $9.4 million in Q3 2024.
• Net Loss: $13.1 million ($3.25 per share) compared to a net loss of $48.3 million ($12.01 per share) in Q3 2024.
• Cash Position: $121.1 million as of September 30, 2025, with a cash runway extended into 2028.

2. Strategic Updates and Business Highlights

• Sale of FibroGen China: Completed sale to AstraZeneca for approximately $220 million, enhancing cash access and extending the company's financial runway.
• FG-3246 Development: Progressing with Phase II trials for FG-3246 and FG-3180 in metastatic castration-resistant prostate cancer (mCRPC). Initial results from an investigator-sponsored trial expected in Q1 2026.
• Roxadustat Development: Positive FDA Type C meeting regarding the regulatory path for roxadustat in treating anemia due to lower-risk myelodysplastic syndromes (MDS). Phase III trial protocol submission anticipated by the end of Q4 2025.

3. Forward Guidance and Outlook

• Revenue Guidance: Total revenues for FY 2025 projected between $6 million and $8 million.
• Operating Costs Guidance: Updated to $50 million to $60 million for FY 2025, representing a 70% reduction from FY 2024.
• Clinical Milestones: Anticipated top-line results from FG-3246 trials and roxadustat regulatory submissions will provide key updates in 2026.

4. Bad News, Challenges, or Points of Concern

• Net Loss: Despite reduced expenses, the company continues to incur significant losses.
• Thrombotic Risk in Roxadustat Trials: Concerns regarding potential thrombotic risks may limit patient enrollment in the upcoming Phase III trial, impacting market potential.
• Cash Runway Impact: If FibroGen decides to independently fund the Phase III trial for roxadustat, it could shorten the cash runway into 2027 unless additional capital is raised.

5. Notable Q&A Insights

• Thrombotic Risk: CEO Thane Wettig indicated that the proportion of patients screened out due to thrombotic risks is uncertain and will depend on FDA discussions and trial outcomes.
• Cost of Phase III Trial: Estimated at $50 million to $60 million, which could affect cash guidance if pursued independently.
• Prostate Cancer Landscape: Wettig discussed the competitive landscape, noting the importance of understanding CD46 expression levels in relation to other targets like PSMA.
• Decision Timeline for Roxadustat: Clarity on whether to proceed independently or seek a partner for the Phase III trial is expected by Q2 2026.

Overall, FibroGen is navigating a transformative phase with a strengthened financial position and focused development strategies, while also addressing potential risks and uncertainties in its clinical programs.